Sign inCreate account

Report workspace tools

NCT05010590ACTIVE_NOT_RECRUITINGanonymous

Anabolic Therapy in Postmenopausal Osteoporosis

Sponsor

Source record

Massachusetts General Hospital

Phase

Source record

PHASE4

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Romosozumab, Denosumab

Indication / condition

AI-normalized

Postmenopausal Osteoporosis

Intervention

Source record

Romosozumab, Denosumab

Source & freshness

Source record

NCT ID

NCT05010590

Original source

ClinicalTrials.gov

Source last updated

Apr 15, 2026

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT05010590

Title

Anabolic Therapy in Postmenopausal Osteoporosis

Sponsor

Massachusetts General Hospital

Status

ACTIVE_NOT_RECRUITING

Phase

PHASE4

Condition raw

Postmenopausal Osteoporosis

Condition normalized

Postmenopausal Osteoporosis

Modality raw

monoclonal antibody

Modality normalized

monoclonal antibody

Target raw

Romosozumab, Denosumab

Target normalized

Romosozumab, Denosumab

Interventions

Romosozumab, Denosumab

Public preview

Source record

In this research study we want to learn more about the effect of two different FDA-approved medications in the treatment of osteoporosis.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Anabolic Therapy in Postmenopausal Osteoporosis

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT05010590

Status

ACTIVE_NOT_RECRUITING

Phase

PHASE4

Sponsor

Massachusetts General Hospital

Executive brief

Investment-Ready Snapshot

In this research study we want to learn more about the effect of two different FDA-approved medications in the treatment of osteoporosis.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedApr 15, 2026
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05010590

Indication

Postmenopausal Osteoporosis

Modality

monoclonal antibody

Target

Romosozumab, Denosumab

Intervention

Romosozumab, Denosumab

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.